Table 1.
The basic information of RCTs
| LB/traditional PAI | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| studies | country | cases | age | female | BMI | AN | EG | control group | follow-up | PA |
| alijanipour 2016 | USA | 59/59 | 64.3/64.9 | 30/32 | 32.3/28.7 | SA | LB266mg | bupivacaine | 6 weeks | Y |
| Bramlett 2012 | USA | 25/34 | 61.1/62.2 | 12.0/23 | 31.2/31.5 | GA | LB266mg | bupivacaine | 36 days | Y |
| collis 2016 | USA | 54/51 | 63.7/63.5 | 29/37 | 34.1/35.7 | GA | LB266mg | ropivacaine, epinephrine, ketorolac, clonidine | 8 weeks | N |
| declaire 2017 | USA | 47/49 | 69.7/67.7 | 26/28 | 31.5/31.9 | SA/GA | LB266mg | ropivacaine, ketorolac, morphine, epinephrine | NM | Y |
| Jain 2016 | USA | 63/62 | 68.3/67.5 | 44/45 | 33.3/33.3 | SA | LB266mg | bupivacaine, epinephrine, morphine | NM | Y |
| mont 2017 | USA | 70/69 | 66/66 | 43/39 | 32.4/31.3 | SA | LB266mg | bupivacaine | NM | Y |
| schroer 2015 | USA | 58/53 | 67/68.6 | 34/32 | 32/32 | SA/GA | LB266mg | bupivacaine | 3 weeks | Y |
| Schumer 2018 | USA | 66/64 | NM | NM | NM | SA | LB266mg | bupivacaine | 6 weeks | N |
| schwarzkopf 2016 | USA | 20/18 | 63/59 | 13/8.0 | 29.3/29.5 | SA | LB266mg | ropivacaine, clonidine, Toradol, Epinepherine | NM | Y |
| smith 2017 | USA | 104/96 | 66/66 | 50/68 | 31.5/31.6 | SA | LB266mg | bupivacaine | 6 weeks | N |
| Snyder 2016 | USA | 35/35 | 67.3/65.6 | 13/20 | 30.68/31.29 | SA/GA | LB266mg | ropivacaine,epinephrine morphine, ketorolac | 10 days | N |
| suarez 2018 | USA | 52/52 | 68.1/67.3 | 33/26 | 30.8/32.01 | SA | LB266mg | bupivacaine,lidocaine epinephrine, morphine, ketorolac | 6 weeks | Y |
| zlotnicki 2018 | USA | 38/40 | 63.2/64.3 | 19/26 | 35.5/35.4 | SA/GA | LB266mg | bupivacaine | NM | N |
AN anesthesia, SA spinal anesthesia, GA general anesthesia, NM not mentioned, PA power analysis